Davidson Kempner Capital Management’s Cytokinetics CYTK Stock Holding History

Davidson Kempner Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-206,844	Closed	-$8.31M	–	210
2025 Q1	$8.31M	Buy	206,844 +27,783	+16%	+$1.28M	0.11%	130
2024 Q4	$8.42M	Sell	179,061 -23,981	-12%	-$1.25M	0.14%	120
2024 Q3	$10.7M	Buy	203,042 +76,604	+61%	+$4.27M	0.22%	100
2024 Q2	$6.84M	Buy	126,438 +89,563	+243%	+$5.41M	0.11%	136
2024 Q1	$2.58M	Buy	+36,875	New	+$2.85M	0.03%	161

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Davidson Kempner Capital Management's CYTK Position: Q2 2025 in Review

Davidson Kempner Capital Management sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 206,844 shares — an estimated $8.31M sold.

Davidson Kempner Capital Management first reported a position in CYTK in Q1 2024 and held it in 5 quarters. The position peaked at $10.7M in Q3 2024. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Davidson Kempner Capital Management reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Davidson Kempner Capital Management sold 206,844 Cytokinetics shares in Q2 2025, an estimated $8.31M.
Davidson Kempner Capital Management first reported a position in Cytokinetics in Q1 2024 and held it in 5 quarters.
Davidson Kempner Capital Management's Cytokinetics position peaked at $10.7M in Q3 2024.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Davidson Kempner Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.